Close Menu

NanoString

Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.

The firm envisions applying its new PlexSet technology to the upper end of multiplex gene expression analysis as well as CRISPR validation applications.

CEO Brad Gray said the firm has outgrown its existing sales model and will be looking to add both new sales leadership and new consumables sales roles.

The company saw growth in almost all parts of its revenue stream, except instruments, including a 69 percent increase in revenue from collaborations.

NanoString said its sequencing technology harnesses its expertise in optical barcodes and that it would develop it for clinical use to complement its existing products.

The GenomeWeb Index rose more than 6 percent in January, outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.

The coverage decision provides Humana's 13 million members with access to the test, which provides a numerical score to assess the risk of disease recurrence.

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco, CA, Day Two

The firm expects full-year revenue growth of up to 39 percent, but fell short of prior guidance for the year.

It was a rough year for biotech stocks — the Nasdaq Biotech Index fell 22 percent even as the Dow gained 13 percent and the Nasdaq gained 8 percent.

Pages

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.